|
Balance Sheet Cash Flow Statement 6455 Nancy Ridge Dr. San Diego, CA 92121-2249 CA Tel. 858-452-6600 Fax 858-626-2851 |
Type: Public
On the web:
http://www.ljpc.com
Employees:
94
La Jolla Pharmaceutical aimed to eliminate diseases. The development-stage firm was working with Toleragens, proprietary therapies that block the abnormal antibody production associated with certain autoimmune disorders without suppressing the entire immune system. Its lead drug candidate was Riquent, a treatment for renal disease associated with lupus. The drug would have been one of the few new drugs for lupus, and was being considered as a treatment for other autoimmune disorders. However, the company ceased most of its operations after trials of Riquent failed in 2009. Adamis Pharmaceuticals has announced it intends to acquire La Jolla Pharmaceuticals.
Key numbers for fiscal year ending December, 2008:
Sales: $0.0M
Net income: ($62.9)M
Officers:
Chairman: Craig R. Smith
President, CEO, Assistant Secretary, and Director: Deirdre Y. Gillespie
VP Finance and Secretary: Gail A. Sloan
Competitors:
Alexion Pharmaceuticals
Biogen Idec
Immunomedics
